ULTIBRO BREEZHALER Inhalation (Dry Powder)/Capsules (Hard Gelatin) for

ULTIBRO BREEZHALER should be stored according to the instructions provided by NOVARTIS PHARMA AG. In general, it is recommended to store ULTIBRO BREEZHALER in a cool, dry place, away from direct sunlight and out of the reach of children.

The duration of treatment with ULTIBRO BREEZHALER may vary depending on the condition being treated and the guidance of your healthcare provider. It is important to follow the prescribed treatment plan and continue taking ULTIBRO BREEZHALER for the recommended duration, even if your symptoms improve. If you have any concerns or questions about the duration of treatment, consult your healthcare provider.

It is important to check with your healthcare provider or read the medication label for specific instructions regarding alcohol consumption while taking ULTIBRO BREEZHALER . Some medications, including ULTIBRO BREEZHALER , may have interactions with alcohol that can reduce effectiveness, increase side effects, or pose other risks to your health. It is best to follow the guidance provided by your healthcare professional.

If you miss a dose of ULTIBRO BREEZHALER , take it as soon as you remember. However, if it is close to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one unless advised by your healthcare provider.

No, do not stop taking ULTIBRO BREEZHALER without consulting your healthcare provider, even if your symptoms improve. It is important to complete the full course of treatment as prescribed. Stopping the medication prematurely may lead to a relapse or incomplete resolution of the condition. If you have concerns about the duration of treatment, consult your healthcare provider for guidance.

It is important to consult your healthcare provider before taking ULTIBRO BREEZHALER if you are pregnant or breastfeeding. They will be able to assess the potential risks and benefits based on your specific situation. Please note that the safety and suitability of ULTIBRO BREEZHALER during pregnancy or breastfeeding may depend on the active substance [Active Substance], concentration 0.05 mg, 0.110mg/Capsule, and the specific recommendations of NOVARTIS PHARMA AG.

The effects of ULTIBRO BREEZHALER on your ability to drive or operate machinery can vary depending on the active substance [Active Substance], concentration 0.05 mg, 0.110mg/Capsule, and individual factors. Some medications may cause drowsiness, dizziness, or other side effects that can impair your judgment or coordination. It is important to read the medication label or consult your healthcare provider to understand any potential effects on your ability to perform tasks that require alertness.

The instructions for taking ULTIBRO BREEZHALER with or without food may vary depending on the medication and the recommendations of NOVARTIS PHARMA AG. Some medications may be more effective when taken with food to enhance absorption or reduce stomach irritation, while others may need to be taken on an empty stomach for optimal absorption. Read the medication label or consult your healthcare provider for specific instructions.

The use of ULTIBRO BREEZHALER in children or elderly individuals may depend on various factors, including the specific medication, type Inhalation (Dry Powder)/Capsules (Hard Gelatin) for, and the recommendations of NOVARTIS PHARMA AG. Some medications may have specific dosing instructions or precautions for these age groups. Consult your healthcare provider or read the medication label for information regarding the safe and appropriate use of ULTIBRO BREEZHALER in children or elderly individuals.